Extract from B.I.BioBankTool analysis report
The transferability and reproducibility of B.I.QUANT-PS was proven as part of an 11 instrument ring test in the International Phenome Center Network (IPCN). Metabolites providing information on liver, kidney and cardiovascular diseases are now accessible in a fast and fully validated analysis under DIN-ISO wet spiking.
B.I.QUANT-PS is also an integral part of the new B.I.BioBankTool™, a solution for biobanks that addresses their increasing need for standardization and quality control (QC). The B.I.BioBankTool QC procedure delivers information on pre-analytics, sample preparation and analytical performance. It gives information on matrix identity and integrity, e.g. for urine, EDTA-plasma, citrate plasma or serum, and it can flag sample degradation. It also confirms fasting/non-fasting, identifies contaminations, as well as reported or unreported medications. The B.I.BioBankTool can generate quantitative information on 150 metabolites in urine, and >140 lipoprotein and small molecule parameters in plasma/serum. Retrospective analysis of previously recorded data is feasible.
Professor Matthias Nauck, Director of the Institute for Clinical and Laboratory Medicine at Medical University of Greifswald, commented: “We are excited about the possibilities of NMR screening in biobank quality control to deliver standardized analytical data for biobank metadata. Having multiple biobanks on the same NMR standards will create a wealth of data from all over the world for integration in support of the development of efficient epidemiological and diagnostic tools. The addition of B.I.QUANT-PS substantially enhances the value of data generated, and the IVDr platform can replace conventional analysis tools, which alleviates the cost pressures in clinical analysis. We just installed our AVANCE IVDr at Greifswald University Hospital and will rapidly expand our analytical offerings to biobanks, and for projects such as the German National Cohort.”